Summit Therapeutics PLC (SMMT) — the earnings record
Computed on 2026-09-18 from the vendor's per-print history with the Print Record's method — no desk-written read yet. An investment research diary, not advice.
The record at a glance
Reactions across the covered prints span -18.3% to +13.0% — the beat column and the reaction column frequently disagree, which is the whole reason the record scores them separately. The street carries est EPS $-0.28 · est revenue ~$0.00B into the next print.
Print by print
| Date | EPS | Revenue | |
|---|---|---|---|
| Jul 26 | 2026-07-23 | ✗ miss | ✗ miss |
| Apr 26 | 2026-04-30 | ✓ beat | ✗ miss |
| Feb 26 | 2026-02-23 | ✗ miss | ✗ miss |
| Oct 25 | 2025-10-20 | ✗ miss | ✗ miss |
| Aug 25 | 2025-08-11 | ✗ miss | ✗ miss |
| May 25 | 2025-05-01 | ✓ beat | ✗ miss |
| Feb 25 | 2025-02-24 | ✓ beat | ✗ miss |
| Oct 24 | 2024-10-30 | ✗ miss | ✗ miss |
| Aug 24 | 2024-08-06 | ✓ beat | ✗ miss |
| May 24 | 2024-05-01 | ✗ miss | ✗ miss |
Report-day close to the close three sessions later on adjusted closes, ±3% bands — the same method as every hand-written card; the Print Record method explains the bands. No reaction chart, metric line or behavior read exists for SMMT yet.
FAQ · from the current data · as of 2026-09-18
Quick answers
How often does Summit Therapeutics PLC beat earnings estimates?
Across the last 10 covered prints (as of the 2026-09-18 card), Summit Therapeutics PLC beat EPS estimates 4 of 10 times and revenue estimates 0 of 10 times, with 0 double beats.
How does SMMT stock react to earnings?
Measured close-of-print-day to the close three sessions later: 2 of the last 10 prints resolved up (beyond +3%), 3 flat, 5 down (as of the 2026-09-18 card) — reactions spanning -18.3% to +13.0%. Beat-or-miss and reaction are scored separately because they frequently disagree.
What was SMMT's biggest earnings reaction?
-18.3% over the three sessions after the Apr 26 print (2026-04-30).
When does Summit Therapeutics PLC report earnings next?
2026-10-19 (2026-10-19 · est EPS $-0.28 · est revenue ~$0.00B). This record is computed from the vendor's per-print history with the Print Record's method; a desk-written card for SMMT does not exist yet. An investment research diary, not advice.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ONC BeOne Medicines AGindustry
- REGN Regeneron Pharmaceuticals Incindustry
- ARGX.BR Argen-Xindustry
- RIGL Rigel Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- SLS Sellas Life Sciences Group Incindustry
- REPL Replimune Group Incindustry
- VCEL Vericel Corp Ordindustry
- VRDN Viridian Therapeutics Incindustry
- KOD Kodiak Sciences Incindustry
- ADMA ADMA Biologics Incindustry
- XNCR Xencor Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- MEDCL.PA Medincell SAindustry
- RPRX Royalty Pharma Plcindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- NEU.AU Neuren Pharmaceuticals Ltdindustry
- EXEL Exelixis Incindustry
- KYMR Kymera Therapeutics Incindustry